Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of December 2013, with a specific reporting date of December 19, 2013. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The primary material event disclosed is the grant of a U.S. patent by the U.S. Patent and Trademark Office. The patent, numbered 8,541,182, was granted on September 24, 2013, and is titled "A Biological Marker for Inflammation."
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the context of the patent grant. The document serves to incorporate a press release regarding the intellectual property milestone by reference.
Investor Verification Checklist
- Verify the scope and commercial applicability of U.S. Patent No. 8,541,182 regarding inflammation markers.
- Confirm the status of the Company's cash reserves and burn rate in subsequent filings, as this 6-K contains no financial data.
- Review the attached press release (Exhibit 99.1) for details on the patent's potential impact on the Company's product pipeline.